Chan Y. Cheah

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 454 citations · Full text

Medicine, Oncology, Pharmacology +12

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 436 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients

Roberto N. Miranda, Tariq N. Aladily, H. Miles Prince et al. · Journal of Clinical Oncology · 2013 · 399 citations · Full text

Medicine, Oncology, Surgery +12

Bacterial Biofilm Infection Detected in Breast Implant–Associated Anaplastic Large-Cell Lymphoma

Honghua Hu, Khalid Johani, Ahmad Almatroudi et al. · Plastic & Reconstructive Surgery · 2016 · 342 citations

Life Sciences, Microbiology, Bacteriology +15